Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Associate Professor of Medicine
Medical Director, OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Manager, Editorial Operations
The primary target audience for the activities includes gastroenterologists, nurses, nurse practitioners, and other healthcare providers who treat patients with ulcerative colitis.
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2020, through November 12, 2021:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Expert commentary from Raymond K. Cross, MD, MS, on management of moderate to severe ulcerative colitis, as reported to Clinical Care Options (CCO)
Experts discuss current best practice for choosing among biologics and other therapeutics for patients with moderate to severe ulcerative colitis from CCO
CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis
Expert video from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease